Significant Accounting Policies Significant Accounting Policies [Text Block] Statistical Measurement [Domain] Statistical Measurement [Domain] Investments Investment, Policy [Policy Text Block] Thereafter Finance Lease, Liability, To Be Paid, After Year Four Finance Lease, Liability, To Be Paid, After Year Four Award Timing Predetermined Award Timing Predetermined [Flag] 2025 (three months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Personnel related research and development expenses Personnel Related Research And Development Expense Personnel Related Research And Development Expense Entity File Number Entity File Number Additional Paid-in Capital Additional Paid-in Capital [Member] Tabular List, Table Tabular List [Table Text Block] Number of shares converted in simple agreement for future equity (in shares) Disposal Group, Including Discontinued Operation, Consideration, Equity Interest Received, Number Of Shares Disposal Group, Including Discontinued Operation, Consideration, Equity Interest Received, Number Of Shares Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Notice period for effective termination Collaborative Agreement, Notice Period For Effective Termination Collaborative Agreement, Notice Period For Effective Termination Schedule Of Cost Sharing Payments And Reimbursements Schedule Of Cost Sharing Payments And Reimbursements [Table Text Block] Schedule Of Cost Sharing Payments And Reimbursements Accounts payable Increase (Decrease) in Accounts Payable Other comprehensive income (loss): Other Comprehensive Income (Loss), Tax [Abstract] Unrealized Holding Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Net loss per share, basic (usd per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Commercial paper Commercial Paper [Member] Schedule of Reconciliation of Segment Loss Before Income Taxes and Total Consolidated Loss Before Income Taxes Schedule of Segment Reporting Information, by Segment [Table Text Block] Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Schedule of Available for Sale Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Principles of Consolidation Consolidation, Policy [Policy Text Block] Stock–based compensation expense Share-Based Payment Arrangement, Noncash Expense 2028 Finance Lease, Liability, to be Paid, Year Three Collaborative agreement, aggregate consideration amount (up to) Collaborative Agreement, Aggregate Consideration Amount Collaborative Agreement, Aggregate Consideration Amount Stock Options Options Issued and Outstanding and ESPP Shares Issuable and Outstanding Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Other general and administrative expenses Other General and Administrative Expense Divestiture of Preclinical Small Molecule Programs Disposal Groups, Including Disposal Of Long-Lived Assets [Text Block] Disposal Groups, Including Disposal Of Long-Lived Assets Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Insider Trading Policies and Procedures [Line Items] Total Share-Based Payment Arrangement, Expense Common stock, shares authorized (in shares) Common Stock, Shares Authorized Issuance of common stock and pre-funded warrants, net of issuance costs of $480 (in shares) Stock Issued During Period, Shares, New Issues Current assets: Assets, Current [Abstract] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Total liabilities and stockholders’ equity Liabilities and Equity Finance Lease, 15 Year Lease Agreement Finance Lease, 15 Year Lease Agreement [Member] Finance Lease, 15 Year Lease Agreement DMSA, Non-Cancellable DMSA, Non-Cancellable [Member] DMSA, Non-Cancellable Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited [Member] Takeda pharmaceutical company limited. Disposal Groups, Including Disposal Of Long-Lived Assets [Abstract] Disposal Groups, Including Disposal Of Long-Lived Assets Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Less: imputed interest Lessee, Operating Lease, Liability, Imputed Interest Lessee, Operating Lease, Liability, Imputed Interest Concentration of Credit Risk and Other Risks and Uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] Liabilities and stockholders' equity Liabilities and Equity [Abstract] Collaborative Arrangement, PTV:PGRN Collaborative Arrangement, PTV:PGRN [Member] Collaborative Arrangement, PTV:PGRN Cover [Abstract] Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Maximum Maximum [Member] General and administrative General and Administrative Expense [Member] Accounting Policies [Abstract] Schedule of Future Minimum Lease Commitments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Research and Development Funding Collaboration Agreement Asset Acquisition [Text Block] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Noncash or part noncash divestiture, milestone payments, to be received Noncash Or Part Noncash Divestiture, Milestone Payments, To Be Received Noncash Or Part Noncash Divestiture, Milestone Payments, To Be Received Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Restricted Stock Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Total future minimum lease payments Operating Lease, Liability Landlord Owned Assets Landlord Owned Assets [Member] Landlord Owned Assets Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Right-of-use asset amortization for finance lease Finance Lease, Right-of-Use Asset, Amortization Entity Shell Company Entity Shell Company Other than DMSA Other than DMSA [Member] Other than DMSA Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Expired (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Disposal Group Name [Domain] Disposal Group Name [Domain] Name Measure Name Number of new contracts Collaborative Arrangement, Number Of New Contracts Collaborative Arrangement, Number Of New Contracts Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Operating lease liability, current Operating Lease, Liability, Current Finance lease, interest expense Finance Lease, Interest Expense Document Fiscal Period Focus Document Fiscal Period Focus Issuances under equity incentive plans (in shares) Stock Issued During Period, Shares, Equity Incentive Plan Stock Issued During Period, Shares, Equity Incentive Plan Peripheral Program License Peripheral Product [Member] Peripheral Product Accounts Receivable Receivable [Policy Text Block] Award Timing Method Award Timing Method [Text Block] Expected to vest (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Date Fair Value Award Type [Axis] Award Type [Axis] Total assets Assets Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Investing activities Cash Provided by (Used in) Investing Activity, Continuing Operation [Abstract] Trading Symbol Trading Symbol 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four Vested and released (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Deferred research and development funding liability Increase (Decrease) In Deferred Liability, Capitalized Research and Development Costs Increase (Decrease) In Deferred Liability, Capitalized Research and Development Costs Entity Address, City or Town Entity Address, City or Town Finance lease, weighted-average discount rate applied Finance Lease, Weighted Average Discount Rate, Percent Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Personnel related general and administrative expenses Personnel Related General And Administrative Expense Personnel Related General And Administrative Expense Assets: Assets, Fair Value Disclosure [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company 2026 Finance Lease, Liability, to be Paid, Year One Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Finance lease, weighted-average remaining lease term (in years) Finance Lease, Weighted Average Remaining Lease Term Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Gain from divestiture of small molecule programs Segment gain from divestiture of small molecule programs Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Operating Lease Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Less: present value adjustment Finance Lease, Liability, Undiscounted Excess Amount Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Accumulated Deficit Retained Earnings [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Steve Krognes [Member] Steve Krognes Venture Backed Private Company ("VBPC") Venture Backed Private Company ("VBPC") [Member] Venture Backed Private Company ("VBPC") Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Purchases of marketable securities Payments to Acquire Marketable Securities Sale of Stock [Domain] Sale of Stock [Domain] Equity consideration received in the divestiture of small molecule programs (Note 10) Equity consideration received Noncash or Part Noncash Divestiture, Amount of Consideration Received Convertible preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Net cost sharing payments (reimbursements) Research And Development Expense, Offset From Cost Reimbursement Research And Development Expense, Offset From Cost Reimbursement Product and Service [Domain] Product and Service [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Exercisable (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Royalty Payment Royalty Payment [Member] Royalty Payment Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] City Area Code City Area Code Expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number Collaboration And Development Funding Agreement Collaboration And Development Funding Agreement [Member] Collaboration And Development Funding Agreement Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Other accrued costs and current liabilities Accrued Liabilities, Current Milestone Triggered Milestone Triggered [Member] Milestone Triggered Private placement pre-funded warrants (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] General and administrative Total general and administrative expenses General and Administrative Expense Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Convertible preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Schedule of Assumptions Used for Estimating the Fair Value of Stock Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] TV Programs, Including Cost Sharing TV Programs, Including Cost Sharing [Member] TV Programs, Including Cost Sharing Schedule of Supplemental Information for Lease Amounts Recognized Lease, Cost [Table Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Vested and expected to vest (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Money market funds Money Market Funds [Member] 2029 Finance Lease, Liability, to be Paid, Year Four Net accretion of discounts on marketable securities Investment Income, Amortization of Discount Lease Contractual Term [Axis] Lease Contractual Term [Axis] Numerator: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Equity Components [Axis] Equity Components [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Product Product [Member] Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Long-term marketable securities: Long Term Marketable Securities [Member] Long term marketable securities. Interest and other income, net Segment interest and other income, net Interest and Other Income Supplemental disclosures of cash flow information Supplemental Cash Flow Information [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other Performance Measure, Amount Other Performance Measure, Amount Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Entity Address, State or Province Entity Address, State or Province Payments for finance lease right-of-use asset Finance Lease, Principal Payments Marketable Securities Marketable Securities, Policy [Policy Text Block] Total current liabilities Liabilities, Current Individual: Individual [Axis] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Disposal Of Long-Lived Assets [Table] Disposal Groups, Including Disposal Of Long-Lived Assets Research and development Research and Development Expense [Member] Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Entity Interactive Data Current Entity Interactive Data Current Operating lease cost Operating Lease, Cost Operating activities Cash Provided by (Used in) Operating Activity, Continuing Operation [Abstract] Costs incurred Oil and Gas, Cost Incurred, Development Cost External research and development expense External Research And Development Expense External Research And Development Expense Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Equity [Abstract] Purchase commitments Purchase Obligation Segment Information Segment Reporting Disclosure [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] U.S. government treasuries US Treasury Securities [Member] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Other Commitments [Line Items] Other Commitments [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Long-term marketable securities Marketable Securities, Noncurrent Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] 2027 Finance Lease, Liability, to be Paid, Year Two Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] LRRK2 Product LRRK2 Product [Member] LRRK2 Product Leases Lessee, Leases [Policy Text Block] Payments for development and manufacturing services Payments for Manufacturing Cost Payments for manufacturing cost. Depreciation and amortization Depreciation, Depletion and Amortization Other non-current assets Other Assets, Noncurrent Entity Central Index Key Entity Central Index Key PEO Name PEO Name Proceeds from sale of common stock Sale of Stock, Consideration Received on Transaction Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Takeda Collaboration Agreement Takeda Collaboration Agreement [Member] Takeda Collaboration Agreement Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Total future minimum lease payments Finance Lease, Liability Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Segments [Axis] Segments [Axis] Exercise price of warrants (usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Class of Stock [Domain] Class of Stock [Domain] Reduction to research and development expense Reduction To Research And Development Expense Reduction To Research And Development Expense Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Stock-Based Awards Share-Based Payment Arrangement [Text Block] Assets Assets [Abstract] Biogen Biogen [Member] Biogen Underlying Security Market Price Change Underlying Security Market Price Change, Percent Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Other Commitments [Axis] Other Commitments [Axis] Forfeited (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Fair Value Measurements Fair Value Disclosures [Text Block] Stockholders' equity: Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Entity Address, Address Line One Entity Address, Address Line One Research and development Total research and development expenses Research and Development Expense Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Accruals and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Operating lease liability, less current portion Operating Lease, Liability, Noncurrent Accrued manufacturing costs Other Accrued Manufacturing Costs, Current Other Accrued Manufacturing Costs, Current Deferred research and development funding liability, current Deferred Liability, Capitalized Research And Development Costs, Current Deferred Liability, Capitalized Research And Development Costs, Current Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Small Molecule Programs, Including Cost Sharing Small Molecule Programs, Including Cost Sharing [Member] Small Molecule Programs, Including Cost Sharing Name of Property [Domain] Name of Property [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Receivable Accounts Receivable, after Allowance for Credit Loss Milestone payments upon achievement of certain clinical, regulatory and sales milestone events Aggregate Clinical Regulatory And Sales Milestone Payment Aggregate Clinical Regulatory And Sales Milestone Payment Entity Registrant Name Entity Registrant Name Collaborative Arrangement Collaborative Arrangement [Member] Other non-current assets Increase (Decrease) in Other Noncurrent Assets Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Document Quarterly Report Document Quarterly Report Common stock issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Total Assets, Fair Value Disclosure Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Number of operating segments Number of Operating Segments 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Granted (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Milestone Payment Milestone Payment [Member] Milestone Payment Non-PEO NEO Non-PEO NEO [Member] Allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Sale of Stock [Axis] Sale of Stock [Axis] Unrealized Holding Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Name Trading Arrangement, Individual Name Equity Award [Domain] Award Type [Domain] 2026 Lessee, Operating Lease, Liability, to be Paid, Year One Equity Awards Adjustments Equity Awards Adjustments [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Compensation Amount Outstanding Recovery Compensation Amount Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Accrued clinical and other research and development costs Accrued Clinical And Other Research And Development Costs, Current Accrued Clinical And Other Research And Development Costs, Current MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Beginning balance (usd per share) Ending balance (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value ATV:Abeta Program License ATV:Abeta Program License [Member] ATV:Abeta Program License Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Collaborative Arrangement, ATV:TREM2 Collaborative Arrangement, ATV:TREM2 [Member] Collaborative Arrangement, ATV:TREM2 Aggregate payments Collaborative Arrangement, Aggregate Payments Collaborative Arrangement, Aggregate Payments 2025 (three months) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Equity securities without readily determinable fair value, impairment loss Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Financial Instruments [Domain] Financial Instruments [Domain] Deferred research funding and development liability, less current portion Deferred Liability, Capitalized Research And Development Costs, Noncurrent Deferred Liability, Capitalized Research And Development Costs, Noncurrent Segments [Domain] Segments [Domain] Future royalties, threshold after first commercial sale Noncash Or Part Noncash Divestiture, Future Royalties, Threshold After First Commercial Sale Future Royalties, Threshold After First Commercial Sale Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] New SLC Finance Lease New SLC Finance Lease [Member] New SLC Finance Lease Non-cash adjustment to operating lease expense Increase (Decrease) In Non-Cash Operating Lease Expense Increase (Decrease) In Non-Cash Operating Lease Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Biogen Collaborative Arrangement Biogen Collaborative Arrangement [Member] Biogen Collaborative Arrangement Minimum Minimum [Member] Number of securities called by warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Company Selected Measure Name Company Selected Measure Name Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Operating cash flows from operating lease Operating Lease, Payments Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Finance lease right-of-use asset Finance Lease, Right-of-Use Asset, after Accumulated Amortization Volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Less: imputed interest Finance Lease, Liability, Imputed Interest Finance Lease, Liability, Imputed Interest Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Weighted average number of shares outstanding, diluted (in shares) Weighted average number of shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Commitments and contingencies (Note 6) Commitments and Contingencies Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Small Business Entity Small Business Stock issuance costs Payments of Stock Issuance Costs Convertible preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Document Transition Report Document Transition Report Total undiscounted lease payments Finance Lease, Liability, to be Paid Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024 Preferred Stock, Value, Outstanding Underlying Securities Award Underlying Securities Amount Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Marketable Securities Cash, Cash Equivalent, and Marketable Security [Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Document Type Document Type Level 3 Fair Value, Inputs, Level 3 [Member] Net Loss Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Additional paid-in capital Additional Paid in Capital Product and Service [Axis] Product and Service [Axis] Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs of $480 Proceeds from Issuance of Common Stock Variable lease costs Variable Lease, Cost Total collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax All Individuals All Individuals [Member] Fair Value Disclosures [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Name Forgone Recovery, Individual Name Fair value of shares converted in simple agreement for future equity Disposal Group, Including Discontinued Operation, Consideration, Equity Interest Received, Value Assigned Disposal Group, Including Discontinued Operation, Consideration, Equity Interest Received, Value Assigned Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Short-term marketable securities: Short Term Marketable Securities [Member] Short term marketable securities. Proceeds from exercise of awards under equity incentive plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Common stock shares outstanding (in shares) Weighted Average Number of Shares Issued, Basic Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Disposal Group Name [Axis] Disposal Group Name [Axis] Private Placement Private Placement [Member] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Short-term marketable securities Marketable Securities, Current Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Effective maturity (less than) Debt Securities, Available-for-Sale, Term Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Current liabilities: Liabilities, Current [Abstract] Net unrealized gain (loss) on marketable securities, net of tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Total operating expenses Operating Expenses Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Level 1 Fair Value, Inputs, Level 1 [Member] Non-cash gain from divestiture of small molecule programs Gain (Loss) on Disposition of Assets Thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Four Lessee, Operating Lease, Liability, To Be Paid, After Year Four Net loss per share, diluted (usd per share) Earnings Per Share, Diluted Pre-Funded Warrant Pre-Funded Warrant [Member] Pre-Funded Warrant Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Therapeutics Segment Therapeutics Segment [Member] Therapeutics Segment Title of 12(b) Security Title of 12(b) Security Off-balance sheet concentrations of credit risk Concentration Risk, Credit Risk, Financial Instruments, Off-Balance Sheet Risk, Amount Concentration Risk, Credit Risk, Financial Instruments, Off-Balance Sheet Risk, Amount Number of common stock sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Earnings Per Share [Abstract] Investments, Debt and Equity Securities [Abstract] Short-term marketable securities: Debt Securities, Available-for-Sale, Current Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Fair value of investment Equity Securities, FV-NI, Noncurrent Less: present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount Exercised (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Award Timing Disclosures [Line Items] Granted (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Accrued compensation Employee-related Liabilities, Current Total undiscounted lease payments Lessee, Operating Lease, Liability, to be Paid Other research and development expenses Other Research and Development Expense Common Stock Equity [Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent Expiration Date Trading Arrangement Expiration Date Other Commitments [Domain] Other Commitments [Domain] Organization and Description of Business Organization and Description of Business, Policy [Policy Text Block] Organization and description of business, policy. Property and equipment, net Property, Plant and Equipment, Net Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Convertible preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Adoption Date Trading Arrangement Adoption Date Disposal Groups, Including Disposal Of Long-Lived Assets [Line Items] Disposal Groups, Including Disposal Of Long-Lived Assets [Line Items] Disposal Groups, Including Disposal Of Long-Lived Assets Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Series A Preferred Stock Series A Preferred Stock [Member] Entity Current Reporting Status Entity Current Reporting Status Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Financing activities Cash Provided by (Used in) Financing Activity, Continuing Operation [Abstract] Loss from operations Operating Income (Loss) Accumulated deficit Retained Earnings (Accumulated Deficit) Name of Property [Axis] Name of Property [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Issuances under equity incentive plans Stock Issued During Period, Value, Equity Incentive Plan Stock Issued During Period, Value, Equity Incentive Plan Class of Stock [Axis] Class of Stock [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Weighted-Average Fair Value at Date of Grant per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Statement [Table] Statement [Table] Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Contract liability Contract with Customer, Liability Schedule of Assets and Liabilities Measured at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Maturities and sales of marketable securities Proceeds from Sale and Maturity of Marketable Securities Finance lease liability, less current portion Finance Lease, Liability, Noncurrent Antidilutive securities, excluded (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Common stock, price per share sold (usd per share) Sale of Stock, Price Per Share Loss before income taxes Income (Loss) Attributable to Parent, before Tax Other Commitments [Table] Other Commitments [Table] Termination Date Trading Arrangement Termination Date Net cash (used in) provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Operating lease, weighted-average discount rate applied Operating Lease, Weighted Average Discount Rate, Percent Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Long-term marketable securities: Debt Securities, Available-for-Sale, Noncurrent Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Weighted average number of shares outstanding, basic (in shares) Weighted average number of shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Restricted cash Restricted Cash and Cash Equivalent, Noncurrent Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Segment Reporting [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Entity Tax Identification Number Entity Tax Identification Number Beginning balance (usd per share) Ending balance (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Sanofi Sanofi [Member] Sanofi [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued (in shares) Common Stock, Shares, Issued Operating lease, weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Use of Estimates Use of Estimates, Policy [Policy Text Block] Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Forfeited (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of RSU shares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Remaining aggregate payments Collaborative Arrangement, Remaining Aggregate Payments Collaborative Arrangement, Remaining Aggregate Payments Total liabilities Liabilities Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Common stock, $0.01 par value; 400,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 146,625,722 shares and 144,220,986 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively Common Stock, Value, Outstanding Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] DMSA DMSA [Member] DMSA. Operating expenses: Expenses Operating Expenses [Abstract] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Collaborative Arrangement, PTV:PGRN and ATV:TREM2 Collaborative Arrangement, PTV:PGRN And ATV:TREM2 [Member] Collaborative Arrangement, PTV:PGRN And ATV:TREM2 Tenvie Therapeutics, Inc Tenvie Therapeutics, Inc [Member] Tenvie Therapeutics, Inc Issuance of common stock and pre-funded warrants, net of issuance costs of $480 Stock Issued During Period, Value, New Issues Statement [Line Items] Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Option Fee Payment Option Fee Payment [Member] Option Fee Payment Counterparty Name [Axis] Counterparty Name [Axis] Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Common Stock Common Stock [Member] Vested and released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Aggregate Fair Value Debt Securities, Available-for-Sale Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Finance Lease Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Corporate debt securities Corporate Debt Securities [Member] Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation